This study is concerned with the development of an agent for single photon emission computer tomography (SPECT) for imaging inflammation and tumor progression. 
Introduction
Non-steroid anti-inflammatory drugs (NSAIDs) have been well recognized for their anti-inflammatory efficacy and cancerpreventing effects. Chronic inflammation is associated with an increased risk of cancer for individuals with inflammatory bowel diseases [1] . Hence, cancer prevention by using NSAIDs is a relevant concept, and reports on their use for this means can be found in literature [2, 3] . Their inflammatory mechanism is mainly associated with inflammatory lipids that are catalyzed by the key enzyme, cyclooxygenase (COX) [4] . Three types of COX enzymes have been reported: (1) COX-1, which functions as a house-keeping enzyme and is constitutively expressed in most tissue types; (2) COX-2, which is a highly inducible enzyme under physiological conditions; and (3) a COX-1 splice variant that is termed COX-3 [5e7]. COX mediates the conversion of arachidonic acid (AA) into prostaglandins (PG) via two sequential steps: initial oxidation to PGG2 by using a cyclooxygenase enzyme and subsequent reduction to an unstable endoperoxide intermediate PGH2 by peroxidase (POX) [8] . The two reactions occur in spatially distinct but mechanistically coupled active sites. The cyclooxygenase active site is located at the end of a long hydrophobic channel that is broad near the membranebinding domain (the lobby) and narrows as it extends toward the interior of the protein [9, 10] . The POX active site is located on the surface of the protein near the heme cofactor. Prostaglandin endoperoxide synthase-1 and -2 (PGHS-1 and -2) are also known as COX-1 and COX-2, respectively [11] . PGHSs are composed of two monomers. Each monomer has a physically distinct COX and POX active site. The two monomers have different conformations, and they function cooperatively during catalysis in solution. It is clear that the COX reaction is activated through a radical cation intermediate of a hemeemonomer complex that is derived from the oxidation of the hemeemonomer complex by POX. The key rests in the fact that the Tyr 385 radical should be formed via POX before the oxidation of AA by COX. COX and POX could maintain their reaction pathways independently. However, the reaction cycle of COX is sensitive and could be terminated by various factors, whereas POX activity is relatively unaffected and can last longer. The mechanism of inhibition of COXs by traditional NSAIDs is complicated because AA and the inhibitor interact with COX reciprocally. In PGHS-1, the conformations of the two AAs in the AA-COX complexes of the dimer are symmetrical. In contrast, the two conformations of AAs in PGHS-2 are antisymmetrical [12] . PGHS-2 functions as a conformational heterodimer with an allosteric monomer (E allo ) and a catalytic (E cat ) monomer. For example, some non-substrate fatty acids could bind E allo to stimulate the rate of AA oxygenation. Some COX inhibitory NSAIDs and some COX-2 specific inhibitors function through E allo , E cat , or both E allo and E cat [13, 14] . In many tumors, high prostaglandin levels are up-regulated by COX, whereas the degraded enzyme e.g., 15 -prostagladin dehydrogenase (15-PGDH) plays a role in the negative regulation of prostaglandin levels.
The long-term uptake of NSAIDs and COX-1inhibitors is always accompanied by adverse side effects such as gastrointestinal toxicity [15, 16] . Specific COX-2 inhibitors were developed to overcome this side effect. However, prolonged use of COX-2 inhibitors results in other side effects such as cardiovascular events. Furthermore, very high dosages of COX inhibitors or NSAIDs are frequently required to exhibit tumor inhibition effects, but only low dosages are required for inhibiting prostaglandin formation [1, 17] . The antitumoral effects are thus probably not only mediated through the COX pathway but also through an NSAID-activated gene or growth differentiation factor 15 [1] .
Because of the complexity of COX mechanisms such as dual functionality of the enzyme and close coupling of the two active sites, agents with unique inhibitory properties are still under development. Apart from the fact that aspirin irreversibly inactivates COX-2 by covalently modifying E cat , other COX inhibitors have been developed such as (a) time-independent E allo inhibitors (ibuprofen with 2-arachidonylglycerol and PGHS-2) or timeindependent E allo and E cat inhibitors (ibuprofen with AA and PGHS-2), and (b) time-dependent E allo inhibitors (naproxen with AA and PGHS-2) [11, 13, 14] . In addition, a number of studies have focused on developing COX-1 selective inhibitors with very low gastric ulcerogenic activities [18, 19] , because inhibiting COX-1 alone is not sufficient to cause gastric damage [20] .
Imaging inflammation as well as tumor progression has attracted a great deal of attention recently [21e36] . As a diagnostic imaging probe for positron emission tomography (PET) or single photon emission computer tomography (SPECT), cytotoxicity is not a serious concern because only very low doses (lower than 1/100 the therapeutic dose) are administered to an individual within a short period [37] . Various PET and SPECT probes based on the structural characteristics of COX-2 [21e35] and COX-1 [36] specific inhibitors have been developed in the past few decades. However, only rare radiopharmaceuticals have been successfully applied to imaging inflammatory events [36] . The reason for this has been attributed to the instability of COX-2 enzymes or due to the very low absolute amount of COX-2 over-expression that is available to be detected [1] .
Because the designs of these radiolabeled COX-2 inhibitors are mainly based on a triphenyl ring scaffold or biaryl scaffold that specifically target the COX-2 enzyme, other types of radiopharmaceuticals that target the COX-1 enzyme have been reinvestigated [38] . Promising imaging results [39] encouraged us to prepare octyl fenbufen amide (OFA) [40e42], which are members of the NSAID family that do not exhibit COX selectivity (Fig. 1) . Specifically, OFA was discovered through parallel solution phase synthesis. Moreover, the octyl group can be used to modify its antitumoral cytotoxicity (EC 50 ¼ 20 mM) in comparison with its parent fenbufen [42] . Arachidonyl ethanolamide (AEA) was reported to be poly-unsaturated fatty acyl amide that exerts immunomodulatory activity through unspecified anchoring to the active site of COX-2 (as well as COX-1) [43, 44] . Because both AEA and OFA share a similar structural feature in terms of their eight-carbon chain length, the inhibition of cellular growth by OFA was postulated to be mediated through such an interaction. Hence, OFA might be a tracer suitable for imaging COX function. Taken together, OFA was chosen for radiolabeling and for imaging of COXs in vivo. Specifically, OFA was labeled with radioiodine 123 I for non-invasive in vivo imaging using SPECT.
Materials and methods

General
All of the reagents and solvents that we used were purchased from Sigmae Aldrich, Malingkrodt, Acros, Alfa, Tedia, or Fluka. CH 2 Cl 2 and toluene were dried over CaH 2 , and MeOH was dried over Mg and distilled prior to use. DMF and 1,4-dioxane were distilled under reduced pressure. The reagents and solvents were reagent grade. Preparation of organostannyl compound 3 was carried out in dried glassware under nitrogen at positive pressure. The eluents that were used for flash chromatography such as EtOAc, acetone, and n-hexane were of industrial grade and distilled prior to use; MeOH and CHCl 3 were reagent grade and used without further purification. Thin layer chromatography (TLC) was performed with MERCK TLC silica gel 60 F 254 precoated plates. The starting materials and products were visualized with UV light (254 nm). Further confirmation was carried out by staining with 5% p-anisaldehyde, ninhydrin, or ceric ammonium molybdate under heating. Flash chromatography was performed using Geduran Si 60 silica gel (230e400 mesh). Melting points were measured with MEL-TEMP and were uncorrected. NMR spectroscopy, including 1 H NMR (500 MHz) and 13 I. The target was washed with dilute NH 4 OH (0.0016 N, 500 mL) and eluted with NH 4 OH (0.16 N, 4 mL). The eluents were immediately loaded onto an alumina-B cartridge that had been pretreated with acetic acid (5.8 N, 10 mL). Followed by loading onto a second column of resin (AG50W-X8) that was pretreated with NaOH (1 N, 4 mL), the eluents were combined (2e3 mL) and a volume that ranged from 0.3 to 0.6 mL was used throughout the subsequent radiolabeling experiment. Radiolabeling was performed in a hood with sufficient ventilation and that had been fitted with a hepafilter for operation with 123 I. [ The settings for the radioactive ligand binding assay included a gel filtration column that consisted of TSKgel G3000PWxl 7.5 Â 300 (mm) with a particle size of 10 mm, which was purchased from Tosoh Bioscience LLC. The corresponding eluting conditions including PBS buffer and flow rate of 1 mL/min were employed throughout the experiment. The identity of [ 123 I]IOFA 2 was confirmed using an authentic sample 2 on the HPLC chromatogram after coinjection. The peak area of the UV absorbance at 254 nm that should have corresponded to authentic sample 2 was calculated by interpolating a standard curve that related mass to UV absorbance. Only a specific activity of below 36 GBq/mmol could be measured accurately. Radioactive measurements were performed using a Capintec R15C dose calibrator. All the in vivo experiments were performed in compliance with the NHMRC Taiwan Code of Practice for the care and use of animals for scientific purposes. Male SpragueeDawley (SD) rats that were 49 weeks old were obtained from the Animal Research Center (Chang-Gung Memorial Hospital, Taiwan). The rats were housed under constant environmental conditions and were allowed free access to food and water throughout the experimental period. In vivo studies were performed in a thioacetamide-induced cholangiocarcinoma rat (37th week post administration) along with a normal rat as a control.
The rats were anaesthetized via inhalant isoflurane (Forthane, Abbott) in 200 mL/min oxygen during the imaging study. SPECT system (X-SPECT/CT, Gamma Media, Northridge, CA, USA) was used for small animal imaging experiments.
Chemical preparation 2.2.1. 4-(4
0 -iodobiphenyl-4-yl)-4-oxobutanoic acid 1 A mixture of succinic anhydride (893 mg, 9.0 mmol) and AlCl 3 (2.52 g, 18.8 mmol, 2.1 eq) in CH 2 Cl 2 (45 mL) was stirred at room temperature for 20 min while the mixture became a milky paste. The viscous mixture was moved to an ice bath and stirred in the dark for 2 min. Upon the addition of commercial 4-iodobiphenyl (2.5 g, 9.0 mmol), the mixture turned dark green. Stirring was then continued for 1 h. TLC (acetone:n-hexane ¼ 3:7) was used to observe the consumption of iodobiphenyl (R f ¼ 0.87) and the formation of product 1 (R f ¼ 0.21). The mixture was poured into a mixture of HCl (12 N, 250 mL) in ice (500 g), and stirring was carried out until the dark green color disappeared, and yellow suspended solids were formed. After filtering the mixtures using a Büchner funnel, the residual solid was collected. The mixture was dissolved in aqueous NaOH (1 N, 250 mL). EtOAc was then added to partition the undesired organic impurities, which were then removed. The aqueous layer was collected and HCl (12 N) was added to acidify the solution until the solids precipitated. The mixture was transferred to a Büchner funnel where it was washed with distilled water to remove the rest of the acid. The residue was dried under reduced pressure, and a fruity yellow solid was obtained at a crude yield of 89% (3.0 g). Although additional purification using HPLC with various eluents was performed, identification of desired product 1 and the deiodinated byproduct was difficult. The ratio of iodo and deiodinated byproducts was determined through structural modification as described in the subsequent preparation. Calcd. C 16 
4-(4
To a two-necked round-bottomed flask that contained a mixture of 1 in DMF (15 mL) was added HBTU (O-benzotriazol-1-yl-N,N,N 0 ,N 0 ,-tetramethyluronium hexafluorophosphate; 998 mg, 2.6 mmol) and diisopropyl ethylamine (680 mg, 0.9 mL, 5.2 mmol, 2 eq) in sequence. Stirring was then carried out for 30 min after which commercial octan-1-amine (510 mg, 3.9 mmol, 1.5 eq) was added. Stirring was then carried out for another 15 min. TLC (acetone/n-hexane ¼ 3:7) was used to observe the consumption of the starting material 1 (R f ¼ 0.21) and the formation of the product 2 (R f ¼ 0.56). The mixture was concentrated under high vacuum at 60 C. The residue was partitioned between aqueous HCl (1 N, 30 mL Â 2) and CHCl 3 (50 mL 2.2.3. N-octyl-4-oxo-4-(4 0 -(trimethylstannyl)biphenyl-4-yl)butanamide 3 To a flask (10 mL) containing IOFA 2 (100 mg, 0.2 mmol) in 1,4-dioxane (1 mL) bis(triphenylphosphine)palladium dichloride (5 mg, 0.007 mmol, 0.03 eq) and hexamethylditin (237 mg, 0.15 mL, 0.72 mmol, 3.6 eq) were added sequentially. The mixture was warmed to 85 C, and stirring was carried out for 15 min. TLC (acetone/CHCl 3 ¼ 1:19) was used to follow the consumption of the starting material 2 (R f ¼ 0.50) and the formation of the product 3 (R f ¼ 0.55). The mixture was filtered through a celite pad, and the filtrates were concentrated under reduced pressure. The residue that was obtained was purified using flash chromatography with the eluent EtOAc/n-hexane ¼ 2:8 to provide a white paste 3 at 56% yield (61 mg). An analytic sample was obtained through fractionation with HPLC using an eluent of EtOAc/n-hexane 
Preradiolabeling of organostannyl compound 3 with non-radioactive NaI
A sample vial (50 mL) that contained NaI (7.8 mg, 0.052 mmol, 7.5 eq) and doubly distilled water (0.5 mL) was sonicated for 2 min. A solution of glacial AcOH and 30% H 2 O 2 (1:1.5 v/v) was added, and sonication was carried out for a further 1 min. After adding the solution of organostannyl compound 3 (4 mg, 0.007 mmol, 1 eq) in CH 2 Cl 2 (2 mL) the mixture was sonicated for 20 min. The quenching reagent Na 2 S 2 O 3 (0.1 M, 10 mL) was then added. Next, the mixture was partitioned by using H 2 O (5 mL) and CH 2 Cl 2 (10 mL). The organic layer was collected for subsequent loading onto a neutral alumina cartridge followed by washing with a solution of CH 2 Cl 2 and MeOH (2:1, v/v, 10 mL). After being concentrated under reduced pressure, the residue was purified with HPLC (Si-100) using the eluent CH 2 Cl 2 :MeOH ¼ 99:1 to provide the desired fractionations: t R ¼ 17.2 min for compound 2 and t R ¼ 18.2 min for the destannylated byproduct OFA (see also the radiochemical labeling section). After being concentrated under reduced pressure, the desired compound 2 was obtained at 50% yield (2 mg).
Radiochemical labeling of 4-(
To a round-bottomed flask (25 mL) that was charged with a mixture of aqueous [ 123 I]NaI (75 mCi) in H 2 O (less than 0.6 mL), glacial AcOH (3.5 mL) and H 2 SO 4 (0.06 mL) were added sequentially. Stirring was then carried out for 1 min. A mixed solution (3.5 mL) of glacial AcOH and aqueous H 2 O 2 (30% wt) at a ratio of 2:3 (v/v) was added and the mixture was vigorously stirred for 1 min. A solution of organostannyl compound 3 (9 mg) in CH 2 Cl 2 (1 mL) was then added, and the mixture was vigorously stirred at room temperature for 20 min. The reaction was quenched by adding Na 2 S 2 O 3 (2 M, 0.8 mL). The mixture was then partitioned and the organic layer was collected, and the residual aqueous layer was back-extracted with CH 2 Cl 2 (1 mL) twice. The organic layers collected were treated with seven large spatulas worth of Na 2 SO 4 and then gravity filtered. The filtrates were loaded onto a CH 2 Cl 2 -preconditioned Alumina N cartridge followed by washing with a mixed solution of CH 2 Cl 2 and MeOH (3 mL, 2:1 v/v). The filtrates were concentrated under reduced pressure, and the residue was further purified with HPLC using the eluent MeOH/ CHCl 3 ¼ 1:99, t R ¼ 15.0 min (Radio). Fractions of [ 123 I]iodooctafenbufen 2 that had been isolated from several injections were combined followed by concentration under reduced pressure to provide [ 123 I]2 at 15% radiochemical yield (8.1 mCi, decay corrected). The specific radioactivity and radiochemical purity were 36 GBq/mmole and 99%, respectively. Regarding animal SPECT imaging, the cholangiocarcinoma tumor-bearing rat and control rat were each injected with 0.76 mCi/1 mL and 1.39 mCi/1 mL, respectively.
Bioassay of competitive inhibition of the substrate transfer (CIST) by COX
The procedure, as stated by the product supplier, was adopted throughout the whole assay. In brief, inhibitors were diluted with ethanol to final working concentrations that ranged either from 10 of COX-1 or COX-2 was added to the above assay buffer (400 mL). All of the reagents including the stock solutions of enzyme, heme, arachidonic acid, and the colorimetric substrate N,N,N',N'-tetramethyl-1,4-benzenediamine dihydrochloride product (TMPD) were cooled in a box that contained dry ice. In addition to uridine and IOFA 2 that were dissolved in H 2 O and DMSO, respectively, the other compounds were dissolved in EtOH. After mixing the above stock solutions of COX (10 mL), heme (10 mL), compound tested (10 mL), assay buffer (150 mL), AA (20 mL) and TMPD (20 mL) to make a total volume of 220 mL. IOFA 2 in EtOH, whereby the concentration ranged from 66 mCi/10 mL to 70 mCi/10 mL. The whole mixture (100 mL) was incubated at 25 C for 15 min followed by purification using HPLC coupled with gel filtration column. PBS buffer (0.1 M, pH ¼ 7.3) was employed as the eluent, and the flow rate was 1 mL/min.
Small animal CT/SPECT imaging study
All in vivo experiments were performed in compliance with the NHMRC Taiwan Code of Practice for the care and use of animals for scientific purposes. Male SpragueeDawley (SD) rats that were 49 weeks old were obtained from the Animal Research Center (Chang-Gung Memorial Hospital, Taiwan). The rats were housed under constant environmental conditions and were allowed free access to food and water throughout the experimental period. In vivo studies were performed in a thioacetamide (TAA)-induced cholangiocarcinoma rat (37th week post administration) along with a normal rat as a control.
The rats were anaesthetized via inhalant isoflurane (Forthane, Abbott) in 200 mL/min oxygen during the imaging study. The imaging study was carried out at the Nuclear Energy Research Institute. SPECT system (X-SPECT/CT, Gamma Media, Northridge, CA, USA) was used for the small animal imaging study. The crude data that was taken from the imaging study were further treated with Preclinical MultiModality Data Analysis software (ver 3.2; PMOD Technologies Ltd, Zurich, Switzerland).
MTT assay (cell viability assay)
The cell toxicity was assessed by a viability assay, MTT (3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) reduction. In brief, T98 (human glioma cell line) cells were plated in the 96-well plate (5000/well) and maintained at 37 C, 5% CO 2 incubator with MEM, 10% fetal calf serum (Gibco, USA). After 24-hour pulse with IOFA, 50 mL of MTT (5 mg/mL) was added to each well for four hours. After removal of medium, 100 mL of DMSO was added to each well and the optical absorbance was determined by a spectrophotometry using a plate reader at 570 nm.
Results and discussion
Radiochemical synthesis
Fenbufen analogs have seldom been reported except for their use in an anti-inflammatory assay of a fenbufen amide library [45] . This might be probably due to its relatively limited structural variability. The reactor-generated radioactive iodide ([
I]I
À ) could be introduced into OFA using a carbon on the aromatic ring. The precursor organostannyl compound 3 was thus prepared via the dehalostannylation of iodooctyl fenbufen amide (IOFA) 2 as outlined in Scheme 1. Nonradioactive IOFA 2 was used to prepare organostannyl compound 3 followed by radioiododestannylation to provide radioactive [ 123 I]IOFA 2 (Scheme 1). The very low polarity of IOFA 2 limited the choice of the eluent during column chromatography. Thus, HPLC was virtually the only tool that was available for purifying IOFA 2 in spite of its limited capacity of 10 mg for each injection. Radiochemical synthesis of [ 123 I]IOFA 2 was relatively straightforward. During the workup, a sufficient amount of drying agent of Na 2 SO 4 was needed. Furthermore, incomplete removal of the residual acetic acid after it was concentrated under reduced pressure was a formidable problem. Thus, an additional procedure for extracting, drying, and concentrating was repeated until the final white solid became odorless. A B Fig. 3 . Inhibition of substrate transfer by COX-1 (A) and COX-2 (B) in the presence of compounds that were tested at various concentrations. Uridine was used as a negative control, whereas Sc-560 and Sc-58125 were used as COXs and COX-2 inhibitors, respectively. Triplicated measurements were performed for each concentration of compounds.
The poor solubility of IOFA 2 in the water-phase based saline solution constituted another challenge because [ 123 I]IOFA 2 was obtained as a white solid after HPLC purification. Prior to injecting it into the tail vein for subsequent animal imaging, the saline solution turned cloudy. Hence, the suspended white particles were filtered twice by using 0.45-mM filters. The relatively low specific activity of [ 123 I]IOFA 2 of less than 37 GBq/mmol was due to the presence of a trace amount of an unknown UV-inactive white solid, which may have decreased its specific activity (Fig. 2) . Please cite this article in press as: Huang H-L, et al., [
Bioassay of competitive inhibition of the substrate transfer (CIST) by COX enzymes
Both the COX-2 selective (SC-58125) and highly COX active but not selective (SC-560) inhibitors were used as controls throughout the assay (Fig. 3) . The assay results showed that IOFA 2 displayed marginal competitive inhibition against the reduction of the colorimetric substrate by COX-1 and COX-2.
The present assay was based on assessing the reduction potential that was catalyzed by POX, which was responsible for the second catalysis of COX. Furthermore, two intermediates were generated from the AA-heme-COX complex that could oxidize N,N,N',N'-tetramethyl-1,4-benzenediamine dihydrochloride (TMPD) to provide the colorimetric product [11, 46] . It has been speculated that POX inactivation involves the oxyferryl heme group, whereas COX inactivation involves a tyrosyl radical [46] . Both of the two positive controls could potentially inhibit POX and thereby block COX function (Table 1) . Specifically, COX-2 inhibition is caused by binding to E cat . These inhibitors are thus classified as being competitive inhibitors. Clearly, IOFA 2 was not one such competitive inhibitor.
As a result, the binding affinity of the substrate toward the first catalytic binding site could not be evaluated very well. Another method that entailed using radioligand binding assay was therefore adopted as is described below.
Radioligand binding assay
The basis of the assay was based on the differential retention times for HPLC of the radioligand-enzyme complexes and the unbound radioligand. Prior to submitting the binding product mixtures for HPLC analysis, a small aliquot of enzyme (10 mL) from the commercial stock solution (200 mL) was introduced to ensure the formation of enough radioligandeenzyme complex prior to analysis. The (Fig. 4) . In contrast, the bound complex with its larger molecular size should have been eluted along the main fractured path thereby traveling at a more rapid speed. Whereas the substrate transfer (CIST) assay showed that IOFA 2 was neither a potent nor selective COX inhibitor, the radioligand binding assay as shown above (Fig. 4) , indicated its preferential binding affinity toward COX-2 rather than COX-1. Its affinity ratio was 1.4:1 when calculated from radioactivity fraction of 76% vs. 56%. Because IOFA 2 did not exhibit a competent inhibition profile similar to that of traditional COX-2 inhibitors, the binding site should be confined to E allo . Its role in regulation might be similar to common non-substrate FAs. Interestingly, IOFA 2 exhibited a cellgrowth inhibition profile when acting against T98 cells (30% inhibition at 10 mM, Fig. 5 ) that differentiates it from common nonsubstrate FAs. Modeling was used to correlate its structure and reactivity (Fig. 6A ). Of note, we observed close contact between Tyr 385 and the amido hydrogen, which might compete with AA to carry out hydrogen abstraction during the first rate-determining step of COX activity (Fig. 6B ). In addition, the biphenyl ring of IOFA 2 mimics the cyclopentane ring of oxidized AA that is formed from the addition of oxygen to AA, which constitutes the second rate-determining step. Thus, IOFA 2 seems to displace AA in terms of COX binding but does not appear to inhibit the formation of the radical cation of Tyr
385
-heme complex as in the case of POX inhibitors. As shown in Fig. 6B , the 8-carbon side chain of IOFA 2 was capable of extending into a narrow bag in the active site that could induce a foot-like fit with the structure of IOFA 2. The foot-like conformation of the IOFA-COX complex may mimic the L-shape conformation of the AA-COX complex. The stabilization that was gained by fitting the octyl side chain might have triggered apoptotic signaling as described for AEA. To serve as a noninvasive imaging tracer in vivo, the binding complex should be durable during imaging processing. In an in vitro monitoring by HPLC with gel filtration column, about half of the radioactivity of the binding complexes was still intact after incubation for 40 min (data not shown). With this information in mind, the subsequent in vivo imaging frame was therefore set from 30 min to 60 min post iv injection.
Tumor imaging
Cholangiocarcinoma (CCA) tumor rat [51e57] was injected with an aliquot of [ 123 I]IOFA 2 (0.76 mCi/1 mL) via tail vein to obtain 1 h worth of SPECT imaging data (Fig. 7 (A) ). The normal rat was injected with the residual aliquot of [ 123 I]IOFA 2 in a dose of 1.39 mCi/1 mL (Fig. 7 (B) ). Although the two injections were conditioned by adjusting the solvent volume to attain equivalent specific activities, the normal rat received more specific activity. The in vivo distribution of radioactivity in the normal rat showed a homogeneous pattern, that was localized mainly in the liver and partly in the heart 30 min post administration (Fig. 7A) . In contrast, a heterogeneous distribution was observed in the liver of the CCA tumor rat. Moreover, those regions that showed hot spots as indicated were equivalent to the white matter in the photograph that was taken of the same rat after it was sacrificed ( (Fig. 7B) , right lower corner). The white matter is an indication of the tumor lesion as judged on the basis of the clinical experience. Specimens of the liver from each of the two rats were further analyzed by histological stainings against both COX-1 and COX-2 (Fig. 8) . Clearly, the positive stainings of both the COX-1 and COX-2 were solely found in the bile duct of CCA tumor rat but not of the normal rat. The higher radioactivity accumulation in CCA rat may be because of a higher expression level of COX (s) or because of mutant COX (s) with higher binding activity. The latter assumption needs to be confirmed in a future study and could not be overridden by the current study. Although [ 123 I]IOFA 2 exerted a mixed COX binding affinity pattern (Fig. 4) , the accumulation of a considerable amount of radioactivity in the heart was remarkable (Fig. 7B ). 
Conclusion
